Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Iptacopan→

Iptacopan Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1644670-37-0
Molecular formula
C25H30N2O4
Molecular weight
422.5 g/mol
Drug class
Complement Factor B Inhibitor
Mechanism of action
Complement Factor B Inhibitors
Indications / reported uses
  • Hemoglobinuria, Paroxysmal
  • adults with paroxysmal nocturnal hemoglobinuria (PNH)
  • adults with complement 3 glomerulopathy (C3G), to reduce proteinuria

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Iptacopan Environmental Risk Assessment (ERA) (the Iptacopan ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.